41 related articles for article (PubMed ID: 22251610)
21. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
[TBL] [Abstract][Full Text] [Related]
23. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
24. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of bone marrow as a metastatic site of human neuroblastoma.
Morandi F; Corrias MV; Pistoia V
Ann N Y Acad Sci; 2015 Jan; 1335():23-31. PubMed ID: 25315505
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission.
Sato M; Yamazaki J; Goto-Koshino Y; Setoguchi A; Takahashi M; Baba K; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2016 Sep; 215():38-42. PubMed ID: 27339366
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications.
Hochheuser C; Windt LJ; Kunze NY; de Vos DL; Tytgat GAM; Voermans C; Timmerman I
Stem Cells Dev; 2021 Jan; 30(2):59-78. PubMed ID: 33287630
[TBL] [Abstract][Full Text] [Related]
29. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
Sabbih GO; Danquah MK
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
[TBL] [Abstract][Full Text] [Related]
30. Bone Marrow Environment in Metastatic Neuroblastoma.
Brignole C; Pastorino F; Perri P; Amoroso L; Bensa V; Calarco E; Ponzoni M; Corrias MV
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069335
[TBL] [Abstract][Full Text] [Related]
31. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
[TBL] [Abstract][Full Text] [Related]
32. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
33. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
34. Monitoring minimal residual disease in AML: the right time for real time.
Jaeger U; Kainz B
Ann Hematol; 2003 Mar; 82(3):139-47. PubMed ID: 12634945
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
